What It Is & Why It Matters Ubisol is a commercially validated, patented formulation platform that solves the critical industry challenge of poor bioavailability in lipophilic compounds (e.g., CoQ10). Co-developed alongside the National Research Council (NRC) through a $40 million investment, Ubisol expands the boundaries of functional product development.
It unlocks premium applications across four multi-billion-dollar sectors: Neurodegeneration therapeutics, Skin Longevity topicals, Personal Health Care supplements, and crystal-clear Energy Waters. How It Works & Methodology The core methodology relies on advanced nanotechnology to encapsulate hydrophobic molecules into thermodynamically stable, 30nm water-soluble nanomicelles. By reducing the particle size to the nanoscale, Ubisol completely bypasses traditional digestive and skin-barrier limitations, allowing the active ingredients to remain perfectly suspended in water-based mediums without phase separation, precipitation, or optical cloudiness. This achieves near-total cellular bioabsorption (~100%) and optimizes transport kinetics across complex biological barriers, including the blood-brain barrier for neuroprotective applications. Proof to Date, Metrics & Validation Plans Backed by extensive datasets from NRC-partnered pre-clinical trials, Ubisol has demonstrated peer-reviewed efficacy in protecting mitochondrial function and mitigating oxidative stress. Ongoing clinical validation plans focus on multi-center pharmacokinetic (PK) human trials to map exact plasma concentration time-curves (C max and AUC) against standard oil-based formulations. Manufacturing metrics confirm exceptional thermal and pH stability, proving zero active degradation under standard high-temperature beverage bottling conditions. Next Steps We are seeking partners/investors. Opportunities include technology acquisition, licensing, or project-specific funding to launch a retail supplement or an energy water lines.
Micillic is a research-focused company specializing in nanotechnology and probiotic technology aimed at neurodegenerative disease treatment. The firm develops innovative formulations, including proprietary probiotic strains and CereQ10 technology, which are designed to influence brain health through the gut-brain axis. By leveraging nano-micelle technology, the company provides expert formulation services that encompass product development, optimization, manufacturing, and quality control.
These research efforts are directed toward addressing complex neurological conditions, such as Alzheimer's and Parkinson's diseases, by targeting gut health. Beyond its scientific research, Micillic functions as a partner for businesses and researchers, offering customized formulation services to bring health and nutritional products from concept to commercialization. The company operates as a privately held entity, maintaining its research initiatives alongside its commercial services for clients in the health, longevity, and nutrition science sectors.